Repositioning Candidate Details
| Candidate ID: | R0608 |
| Source ID: | DB04570 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Latamoxef |
| Synonyms: | Festamoxin; Lamoxactam; Latamoxef; Moxalactam |
| Molecular Formula: | C20H20N6O9S |
| SMILES: | [H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O |
| Structure: |
|
| DrugBank Description: | Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. |
| CAS Number: | 64952-97-2 |
| Molecular Weight: | 520.473 |
| DrugBank Indication: | Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI. |
| DrugBank Pharmacology: | Latamoxef works by inhibiting bacterial cell wall biosynthesis. |
| DrugBank MoA: | Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain (the penicillin-binding protein) by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor. |
| Targets: | Penicillin-binding protein 3 inhibitor; Penicillin-binding protein 1A inhibitor; Penicillin-binding protein 1B inhibitor; D-alanyl-D-alanine carboxypeptidase DacB inhibitor |
| Inclusion Criteria: | Indication associated |
